Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

被引：0
作者：
Hsin-Fu Lee
Chi Chuang
Pei-Ru Li
Yung-Hsin Yeh
Yi-Hsin Chan
Lai-Chu See
机构：
[1] New Taipei City Municipal Tucheng Hospital,Division of Cardiology, Department of Internal Medicine
[2] Chang Gung Memorial Hospital,The Cardiovascular Department
[3] Chang Gung University,College of Medicine
[4] Chang Gung University,Graduate Institute of Clinical Medical Sciences, College of Medicine
[5] Chang Gung University,Department of Public Health, College of Medicine
[6] Chang Gung Memorial Hospital,Microscopy Core Laboratory, Guishan Dist
[7] Chang Gung University,Biostatistics Core Laboratory, Molecular Medicine Research Center
[8] Chang Gung Memorial Hospital,Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine
来源：
Diabetology & Metabolic Syndrome | / 15卷
关键词：
Sodium glucose co-transporter 2 inhibitors; Peripheral artery disease; Revascularization; Diabetes; Dipeptidyl peptidase-4 inhibitors; Amputation; Cardiovascular;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 232 条
[1]  
Low Wang CC(2016)Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations Circulation 133 2459-2502
[2]  
Hess CN(2017)2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Circulation 135 e726-e779
[3]  
Hiatt WR(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-657
[4]  
Goldfine AB(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128
[5]  
Gerhard-Herman MD(2019)Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 380 347-357
[6]  
Gornik HL(2015)Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 373 232-242
[7]  
Barrett C(2019)Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial JAMA 321 69-79
[8]  
Barshes NR(2013)Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 369 1327-1335
[9]  
Corriere MA(2013)Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 1317-1326
[10]  
Drachman DE(2006)Peripheral arterial disease in patients with diabetes J Am Coll Cardiol 47 921-929
12345678910